Abstract Since the 1990's
Introduction
Since the mid-1960s, the Japanese government has advocated gastric cancer screening programs based mainly on double-contrast barium X-ray (1) . As a result, a significant reduction in mortality and morbidity from gastric cancer has been attained (2) (3) (4) (5) (6) . However, the number of people who undergo gastric cancer screening has not increased in recent years. Since 
the 1990's, the test for serum pepsinogen (PG) as a marker for chronic atrophic gastritis has been incorporated into gastric cancer screening programs, on a trial basis, to identify people who would benefit most from gastric cancer screening (7-12). Ever since PG assay kits became commercially available, numerous centers in Japan have measured serum PG levels as a part of gastric cancer screening. The results have shown that PG testing is useful in detecting early-stage gastric cancer (7-12). After 15 years of experience, the effectiveness of PG testing is receiving wide recognition. The present article summarizes the clinical importance of PG testing and introduces our recent investigations on gastric cancer screening programs incorporating PG testing.

Pepsinogen Testing
Pepsinogen is a precursor for pepsin, a digestive enzyme specifically produced in the gastric mucosa. The human stomach expresses two isozymogens, PGI and PGII, with different biochemical and immunological properties (13) . Histological studies based on immunohistochemistry using specific antibodies or in-situ hybridization have clearly identified cells that produce PGI and PGII (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . It is important to note that, during the process of chronic atrophic gastritis, mucosal atrophy advances from the side of the pyloric gland towards the oral side, and that PGI levels and PGI/PGII ratios decrease with advancement in mucosal atrophy (18) (19) (20) 23) (Fig. 2) . These clinically extremely important changes in serum PG levels are due to the above-mentioned unique distribution of PGproducing cells in gastric mucosal epithelia. In addition, the results of past pathological and epidemiological studies have shown that a strong correlation exists between chronic atrophic gastritis and differentiated gastric cancer development, and thus, chronic atrophic gastritis is considered to be a precancerous lesion (24) (25) (26) (27) 
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PG(-); Group B, HP(+) PG(-); Group C, HP(+) PG(+); and Group D, HP(-) PG(+). In other words, Group
These findings suggest that, in the future, gastric cancer screening should be performed after assessing individual cancer risk based on the combination of serum PG levels and HP antibody. Needless to say, highly sensitive radiography such as DR will improve the efficiency of gastric cancer screening.
